How AI Healthcare Startups Raised $681 Million in November

Stay Updated for Free | Follow us on X

November didn’t quite match October’s adrenaline rush, but it still held its own. The month brought a strong focus on diagnostics and patient monitoring, signaling a shift toward refining precision care.

If October was about scaling bold, headline-grabbing solutions, November felt more like a recalibration, less flash, more focus. Think of it as the industry catching its breath while quietly laying the groundwork for the next big leap. If you missed our last month’s report, read it all here!

I’ll walk you through the highlights: who raised what, where it happened, and the trends you should keep an eye on.

Let’s see what we’ve got!

1. Overview

November’s funding story took a turn. With $681.7 million raised across 37 deals, it’s a noticeable drop from October’s $1.51 billion and 49 startups. The pharma sector also hit a low, seeing its weakest merger and acquisition activity in nearly a decade at $67.2 billion by late November. It seemed like October was all gas while November hit the brakes and looked around.

Some big players still made waves. Enveda Biosciences led with $130 million for its AI-driven hunt for natural compounds in drug discovery. Precision brought in $93 million, refining clinical trials with data, and Cradle landed $73 million to supercharge protein design with generative AI. Fewer fireworks, but still plenty of sparks.

The shift from blockbuster deals to specialized solutions says a lot about where the field is heading. Diagnostics and patient care technologies got the spotlight, aligning with the growing push for precision medicine. It’s a shift the World Economic Forum has been pointing to: AI reshaping how we diagnose, treat, and care for patients.

And then there’s the global economy. High interest rates and market jitters didn’t stop investors from backing AI healthcare startups. It’s a quiet vote of confidence, choosing practical, high-impact tools over moonshots. November wasn’t loud, but it was deliberate, laying solid groundwork for what’s next in personalized medicine.

2. Funding Breakdown by Application

Diagnostics and treatment planning led November’s funding, bringing in $222 million across 12 startups. With healthcare systems stretched thin by rising patient demand and staffing shortages, investments in faster, more accurate diagnostics are meeting a critical need. The pandemic might be in the rearview, but the lessons it taught about the importance of robust diagnostic tools are still driving this space forward.

Patient monitoring and care technologies raised $164 million from 9 startups. Remote monitoring and wearable devices are gaining traction as foundational tools in managing chronic diseases and improving patient outcomes. The healthcare industry’s shift toward personalized, proactive care models is keeping this sector at the forefront of innovation.

Drug discovery and development secured $139 million from just 3 startups. The smaller number of players signals a focus on niche, high-potential technologies like generative AI and molecular modeling. These approaches are reshaping how new therapies are discovered, promising faster timelines and lower costs in drug development.

Surgical assistance saw no activity this month. Investors appear to have shifted their attention toward broader-impact areas such as diagnostics and patient care. Administrative tools and AI-driven scientific research, while smaller in scale, continued to attract steady funding, underlining their role in driving operational efficiency and innovation.

November’s funding trends reflect a strategic prioritization of healthcare’s most immediate challenges. The emphasis on diagnostics, patient monitoring, and drug discovery shows a clear intent to invest in solutions that improve care delivery and outcomes while addressing systemic inefficiencies.

3. Funding Breakdown by Stage

November’s funding painted a clear picture of where the focus is shifting. Series C came out on top, with the biggest share of dollars going to startups ready to scale. Investors are clearly hedging their bets on companies that aren’t just ideas anymore—they’ve proven they can deliver and are now positioned to dominate their markets. With the current economic climate, it feels like a safety-first approach.

Seed and Series A rounds didn’t slow down, funding the most startups this month. These early stages are where the magic begins—new ideas, fresh teams, and plenty of potential. Diagnostics and patient monitoring seem to be favorites here, and it’s no surprise. The need for innovative, scalable solutions in these areas is huge, and investors know it.

Series B funding, though, took a step back compared to October. Maybe it’s about investors splitting their focus between the next big thing (early stage) and the sure bets (later stage). The middle ground seems to be losing some love, for now.

Then there’s the near silence on pre-seed and venture capital. It’s hard not to see this as a cautious move—backing startups that already have traction feels like the safer play in an unpredictable market.

What we’re seeing here isn’t random. It’s a calculated balance: fueling the fire for new ideas while doubling down on those already delivering impact. It’s a strategy that says investors are still optimistic, just a little more cautious about where they place their chips.

4. Geographical Trends

The United States dominated AI healthcare funding, securing 68.9% of the $681.7 million total. However, this marks a 14% drop from October’s 80% share. The shift may reflect market jitters surrounding the U.S. presidential election. Election cycles often introduce uncertainty, with investors cautious about potential regulatory or policy changes that could impact healthcare and AI sectors. Even with the dip, the U.S. remains a powerhouse, with its ecosystem of startups, research institutions, and venture capital firms keeping it at the forefront.

Switzerland made a strong showing, capturing 13.2% of the month’s funding—the highest share it has achieved this year. The country’s focus on precision medicine and pharmaceuticals appears to be paying off, particularly in Zurich, where healthcare AI startups continue to draw significant venture capital attention.

Germany held steady, securing 4.7% of the funding. Its ongoing investments in digital health and AI-driven public healthcare solutions are attempting to secure its position as a European leader in healthcare innovation.

The UK, by contrast, slipped to 2.2% from 10.7% in October. Regulatory and policy challenges seem to be a factor. A recent NHS England report highlights how misaligned regulations are stifling domestic innovation, driving some breakthroughs to international markets.

This month’s funding reflects a growing global spread. While the U.S. continues to lead, Switzerland and other European nations are gaining ground, hinting at a future where innovation hubs are more widely distributed across the globe.

5. Final Thoughts

November’s funding trends reveal a healthcare AI sector moving with intent. The U.S. remains at the top, but its slight decline shows a growing shift toward global diversification. Countries like Switzerland and Germany are making their mark, proving that innovation is finding new homes beyond traditional hubs. This broadening of the landscape is more than geographic—it reflects a deliberate push to invest in fresh ideas and untapped markets.

The dip in Series B funding and the absence of surgical assistance investments hint at investors recalibrating. There’s a clear preference for solutions with immediate impact, such as diagnostics and patient care, alongside early-stage innovations and proven technologies ready to scale. It’s a strategy that balances short-term wins with long-term potential.

Patient-centered technologies remain the core focus. From diagnostics to wearables to drug discovery, the aim is consistent: better outcomes, fewer inefficiencies, and smarter care. As the year comes to a close, the healthcare AI space feels less like a chaotic race and more like a measured progression toward meaningful breakthroughs.

Hope you enjoyed this month’s review, see you back next month!